Orthocell raises $17m to fast-track nerve repair device launch in the U.S.
Proactive Investor UK - 25-Oct-2024Funding speeds U.S. entry and scales production as Orthocell advances global expansion
Join the club for FREE to access the whole archive and other member benefits.
Regenerative medicine company empowering the body to heal
It is a regenerative medicine company dedicated to the development of novel collagen medical devices and cellular therapies for the repair and regeneration of human tendons, bone, nerve and cartilage defects.
CelGro® is a naturally derived collagen medical device for tissue repair. CelGro® is designed for use in multiple indications to augment the surgical repair of tendons, bone, peripheral nerves and articular cartilage. CelGro® has distinct competitive advantages over existing tissue repair devices, particularly in the areas of cell compatibility, mechanical properties (strength and ease of use) and facilitating high quality tissue repair making. CelGro® is approved for sale within the European Union for a range of dental bone and soft tissue procedures and is being readied for first approval in the US and Australia.
Ortho-ATI® is a first-in-class cell therapy for treatment of chronic tendon injuries. The unique treatment uses each patient’s own tendon-derived cells to stimulate tendon regeneration, delivered via ultrasound guided injection under local anaesthetic. Ortho-ATI® addresses a significant unmet clinical need in the healing of tendons which are resistant to existing therapies.
Visit website: https://www.orthocell.com.au/
Details last updated 21-Jun-2021
Funding speeds U.S. entry and scales production as Orthocell advances global expansion
Peripheral nerve repair could benefit 3 million patients every year